# US 2026/0226096 A1 · Modified proteins or peptides for covalent targeting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0226096 A1
- Document ID: US20260226096A1
- Status: Published application
- Kind: A1
- Application number: 19/153,980
- Filed: 2024-02-20
- Published: 2026-08-06
- Earliest claimed: 2023-02-20
- Assignees: Yeda Research and Development Co. Ltd.
- Applicants: Yeda Research and Development Co. Ltd.
- Inventors: Nir LONDON; Ronen GABIZON; Barr TIVON; Rambabu REDDI
- Web page: https://patentgrep.com/patent/US20260226096A1

## CPC

- C07K 1/1072: {by covalent attachment of residues or functional groups}
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 1/1075: {by covalent attachment of amino acids or peptide residues}
- C07K 1/1133: {by redox-reactions involving cystein/cystin side chains}
- C07K 7/06: having 5 to 11 amino acids
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention is directed to modified proteins or modified peptides (modified by an electrophile, such as acrylamide or acrylate) for covalent binding with target proteins.

## Claims

### Claim 1

A modified protein or a modified peptide comprising a recombinant protein or a synthetic peptide modified by an electrophile, wherein the electrophile is covalently bound to a thiol group of a cysteine within the protein or peptide; wherein the electrophile is represented by the structure of Formula I;
wherein,
R1 comprises substituted or unsubstituted alkyl, alkenyl, alkynyl, carbocycle, aryl, heteroaryl or heterocyclic;
X comprises O, NR3 or substituted or unsubstituted alkylene; and R3 is hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, carbocycle, aryl, heteroaryl or heterocyclic;
wherein the modified protein or modified peptide is capable of covalently binding a target protein.

### Claim 2 (depends on 1)

The modified protein or modified peptide of claim 1, having a non-covalent recognition with the target protein and the electrophile is in close proximity to a target residue of the target protein; prior to the covalent binding with the target protein.

### Claim 3 (depends on 2)

The modified protein or modified peptide of claim 2, wherein the target residue within the target protein is a cysteine residue (SH) or a lysine residue (NH2).

### Claim 4 (depends on 2)

The modified protein or modified peptide of claim 2, wherein the close proximity comprises a distance being less than 15 Å between the electrophile and the target residue.

### Claim 5 (depends on 1)

The modified protein or modified peptide of claim 1, wherein the electrophile is represented by the structure of Formula II:

### Claim 6 (depends on 1)

The modified protein or modified peptide of claim 1, wherein the electrophile is ethyl methacrylate.

### Claim 7 (depends on 1)

The modified peptide of claim 1 comprising the following peptides: Ac-RSApSmCPSL-NH2 (SEQ ID 3), Ac-RAHpSmCPASLQ-NH2 (SEQ ID 8) or Ac-RAHpSSPASmCQ-NH2 (SEQ ID 11); wherein pS is Phoshoserine and mC is methacrylate-modified cysteine.

### Claim 8 (depends on 7)

The modified peptide of claim 7, wherein the peptide covalently binds 14-3-3 target protein.

### Claim 9 (depends on 8)

The modified peptide of claim 8, wherein the peptide covalently binds Cys38, Lys 122 or Lys 49 of 14-3-3σ target protein.

### Claim 10 (depends on 1)

The modified protein of claim 1 comprising a modified immunity (Im9) protein (SEQ ID 27).

### Claim 11 (depends on 10)

The modified protein of claim 10, wherein the Im9 protein (SEQ ID 27) binds an E9 target protein.

### Claim 12 (depends on 1)

A method of preparing a modified protein or a modified peptide of claim 1, wherein the method comprises;
a. identifying a target protein;
b. designing a peptide or protein covalent binder candidate based on previously characterized noncovalent binders of the target protein;
c. synthesizing a modified peptide or a modified protein, to allow recognition with the target protein at the recognition site; wherein said modified protein or modified peptide comprise a cysteine which is reacted with an electrophile of Formula I.

### Claim 13 (depends on 12)

The method of claim 12, wherein the design of the peptide is based on computational modeling comprising Rosetta CovPepDock.

### Claim 14 (depends on 12)

The method of claim 12, wherein the modified peptide is synthesized from unprotected peptides.

### Claim 15 (depends on 12)

The method of claim 12, wherein the modified protein is synthesized from recombinant proteins.

### Claim 16 (depends on 1)

A protein-protein covalent conjugate comprising a modified protein of claim 1, covalently bound to a target protein, wherein the modified protein and the target protein possess non-covalent recognition prior to the covalent binding with the target protein.

### Claim 17 (depends on 16)

The protein-protein covalent conjugate of claim 16, wherein the modified protein is Im9 protein and the target protein is E9.

### Claim 18 (depends on 17)

The protein-protein covalent conjugate of claim 17, wherein the conjugate displayed a higher thermal stability than the noncovalent complex.

### Claim 19 (depends on 1)

A peptide-protein covalent conjugate comprising a modified peptide of claim 1, covalently bound to a target protein, wherein the modified peptide and the target protein possess non-covalent recognition prior to the covalent binding with the target protein.

### Claim 20 (depends on 19)

The peptide-protein covalent conjugate of claim 19, wherein the modified peptide is Ac-RSApSmCPSL-NH2(SEAQ ID 3), Ac-RAHpSmCPASLQ-NH2 (SEQ ID 8) or Ac-RAHpSSPASmCQ-NH2 (SEQ ID 11); wherein pS is Phoshoserine and mC is Methacrylate-modified cysteine; and the target protein is 14-3-3.

### Claim 21

(canceled)
